CytoDyn Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted net asset / option value: estimated ~$8M net cash remaining after the recent $16.5M financing and ongoing burn, plus a heavily risk-adjusted ~$25M (5% probability-weighted) value for leronlimab's remaining oncology/HIV combination-therapy optionality against an assumed ~$500M un-risked peak value if successful; total ~$33M divided by ~1.43B shares outstanding (from $295.11M market cap / $0.21 share price).

Reasoning: CytoDyn carries recurring 'going concern' disclosures, a long history of failed or inconclusive leronlimab trials, and continuous dilutive financing, so a conventional DCF of future product cash flows is not credible; a heavily risk-adjusted option-value approach anchored to near-term cash and a low probability of clinical/commercial success better reflects intrinsic value than the speculative market price.